Nephrology

DaVita Giving Foundation Invests $1 Million in Western Governors University to Support Nursing Students

Retrieved on: 
星期二, 十二月 19, 2023
Workforce, Nephrology, LSH, University, Student, IA Financial Group, City, Health, Retirement, Start Early, Education, Love, DaVita Inc., WGU, Curriculum, Nursing

DENVER, Dec. 19, 2023 /PRNewswire/ -- The DaVita Giving Foundation has awarded Western Governors University's (WGU) Michael O. Leavitt School of Health (LSH) a $1 million grant over the next three years to support more than 1,500 nursing students in Start Early, a program co-created by DaVita Inc. and WGU to help increase nursing degree completion at the university nationwide.

Key Points: 
  • DENVER, Dec. 19, 2023 /PRNewswire/ -- The DaVita Giving Foundation has awarded Western Governors University's (WGU) Michael O. Leavitt School of Health (LSH) a $1 million grant over the next three years to support more than 1,500 nursing students in Start Early , a program co-created by DaVita Inc. and WGU to help increase nursing degree completion at the university nationwide.
  • The WGU Start Early program will provide resources for nursing students who demonstrate financial barriers to their education and will support their efforts to complete their nursing degree.
  • Additionally, through the funding from the DaVita Giving Foundation, up to 80 students annually will receive critical, need-based scholarships to help them afford their education.
  • Underserved student populations include students of color, students with comparatively lower incomes, students in geographically remote areas and/or students who are the first in their families to attend a university.

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retrieved on: 
星期二, 十一月 14, 2023
Chronic kidney disease, Neutrophil, Acute respiratory distress syndrome, STEC-HUS, Cardiorenal syndrome, Safety, Food, Hepatorenal syndrome, University, AKI, HDE, Risk, ICU, Clinical trial, Monocyte, Mortality, CBER, Sepsis, Patient, Nephrology, Insurance, Research, Letter, Dialysis, Approvable letter, FDA, G&A, Child, Standard of care, Acute kidney injury, Partnership, Nephron, Clinical study design, R, Hospital, SCD, Physician, CKRT, Karger Publishers, PMA, HIV disease progression rates, Pharmaceutical industry, Nursing, Dietary supplement, Cryptocurrency

DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Key Points: 
  • DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, reports financial results for the three and nine months ended September 30, 2023 and provides a business update.
  • “Recent clinical and regulatory successes have significantly improved and strengthened our company’s prospects,” said Eric Schlorff, SeaStar Medical CEO.
  • SeaStar Medical expects regulatory approval for the SCD-ADULT in the first half of 2025 and commercial launch in the second half of 2025.
  • The Company issued two convertible notes each for $0.5 million in August 2023 and a third convertible note for $0.5 million in September 2023.

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
星期二, 十一月 14, 2023
NDA, Chronic kidney disease, Hyperphosphatemia, Chemistry, Food, Therapy, Type, IND, Kidney disease, Clinical trial, Administration, Insurance, Patient, LOS, Agency, Research, Dialysis, FDA, Pharmacokinetics, Nephrology, Trial of the century, R, CMC, Research and development, Doctor of Philosophy, American Journal, Society, Travel, Drug development, Pharmaceutical industry, Management, OLC

LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • LOS ALTOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • We also remain very active within the the medical community with a booth at Kidney Week and positive results published on the phosphate binding capacity for OLC,” concluded Dr. Gupta.
  • Unicycive believes that results from this pivotal trial will enhance the OLC data package from preclinical studies and our previously disclosed bioequivalence study.
  • Dr. Kenkare-Mitra brings Unicycive expertise spanning research, preclinical and clinical development, translational medicine, manufacturing, and regulatory.

ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates

Retrieved on: 
星期一, 十一月 13, 2023
Chronic kidney disease, Webcast, QP, Renal replacement therapy, GMP, Specialization, International, Physician, Kidney failure, Kidney disease, CVS Health, Risk, Surgeon, Glomerular filtration rate, Data, Patient, Framingham Heart Study, Dialysis, CKD, Boston University, Internal medicine, Baxter International, Albuminuria, Documentation, Health, Nephrology, Business administration, Conference, REACT, Trial of the century, EGFR, Quality of life, Memorial University of Newfoundland, Kellogg School of Management, Commercialization, Medical device, Pharmaceutical industry, Cryptocurrency

Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.

Key Points: 
  • Positive interim Phase 2 data demonstrate the potential of REACT® to preserve kidney function in moderate and high-risk diabetic CKD patients.
  • Updated interim REACT RMCL-002 study data support continued investigation of REACT’s potential to benefit patients with moderate and high-risk diabetic CKD.
  • The ongoing Phase 2 clinical study assessed adverse events and changes in kidney function as measured by estimated glomerular filtration rate (eGFR), as primary study endpoints.
  • Further, you may listen to the presentation by dialing 1-877-407-0784 (US) or 1-201-689-8560 (International) and entering the Conference ID: 13742672.

Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results

Retrieved on: 
星期一, 十一月 13, 2023
Molecule, Ophthalmology, Visual acuity, Investment, HD, EMA, Research, Kidney, Autoimmune disease, Driver, C3, Conference, R, Facial muscles, Inflammation, Treatment, Meta-analysis, American Academy, American Society of Nephrology, G&A, Guillain, Society, Letter, Paratriathlon, European Medicines Agency, American Academy of Ophthalmology, Professional, C4, AAO, System, Nephrology, AMD, Immunoglobulin therapy, PACA, Plasma, Disease, Complement component 1q, Medicine, Complement system, FDA, Geographic atrophy, GBS, ARCHER, C5, HIV disease progression rates, Risk management, Pharmaceutical industry, Vaccine, Cryptocurrency, Patient, LN, ALS

EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.

Key Points: 
  • EMA orphan drug designation requires that a novel rare disease therapeutic demonstrates the potential for significant benefit over available therapies.
  • Importantly, Annexon also announced that it has achieved target enrollment of 225 patients in the randomized, double-blind, placebo-controlled Phase 3 trial of ANX005 in patients with GBS.
  • Research and development (R&D) expenses: R&D expenses were $27.9 million for the quarter ended September 30, 2023, reflecting the advancement of the company’s priority programs, including GBS, GA and ANX1502, compared to $27.9 million for the quarter ended September 30, 2022.
  • General and administrative (G&A) expenses: G&A expenses were $6.9 million for the quarter ended September 30, 2023, compared to $8.2 million for the quarter ended September 30, 2022.

ULTOMIRIS: A Complement Inhibitor for Treating Adult Patients with PNH - Drug Insights and Market Forecasts to 2032 with Focus on 7MM - ResearchAndMarkets.com

Retrieved on: 
星期四, 十二月 14, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Research, Immune system, Hematology, Clinical trial, PNH, Patient, Neurology, SWOT, EU4, Hemolysis, Nephrology, Complement component 5, C5a, Inflammation, Risk management, Vaccine, Pharmaceutical industry

This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.

Key Points: 
  • This report provides comprehensive insights about ULTOMIRIS for paroxysmal nocturnal hemoglobinuria (PNH) in the seven major markets.
  • The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities.
  • Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for PNH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PNH.
  • ULTOMIRIS is a complement inhibitor for treating adult patients with PNH.

CORE Kidney Unveils 2024 Rose Parade® Float - A Tribute to the Kidney Donors Who Gifted a Part of Themselves to Save a Life

Retrieved on: 
星期二, 十一月 28, 2023
Other Philanthropy, Managed Care, General Health, Health, Philanthropy, Fund Raising, Foundation, Other Health, Kidney disease, Disease, Insurance, Patient, Multimedia, CORE, Kidney, Butterfly, Nephrology, Lupus nephritis, Rose Parade, Death, UCLA Health, Education, Family, Symbolism, Knowledge, Neuropsychology, Professor, Life, Transport, Pharmaceutical industry

CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.

Key Points: 
  • CORE Kidney’s mission is to bring light to how widespread kidney disease is, with the goal of inspiring more people to take preventive measures.
  • CORE Kidney is sending a direct message to the donors across the world to honor their courageous journey.
  • “To all the living kidney donors around the world, CORE is humbled by your life saving donation.
  • Green ribbon: a symbol of kidney health — a call back to the Green Ribbon Campaign started in 2016 by CORE Kidney that raised awareness for kidney health.

Children’s Hospital Los Angeles Recognized as National Surgical Quality Partner by American College of Surgeons

Retrieved on: 
星期二, 十一月 21, 2023
Nursing, Managed Care, Teens, Surgery, Health, Children, Hospitals, Consumer, Digestive system surgery, Children's Hospital Los Angeles, Senior, Anesthesia, Trauma, Cardiology, ACS, SQP, Trauma Center, Patient, Multimedia, FAAP, Division, American College, FACS, Master of Science, News, MBA, MD, Nursing care plan, CHLA, Pediatric surgery, American College of Surgeons, Dentistry, Management, Orthopedic surgery, Surgeon, Urology, Neonatology, Nephrology

Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.

Key Points: 
  • Children’s Hospital Los Angeles (CHLA) has been recognized as a National Surgical Quality Partner (SQP) by the American College of Surgeons (ACS) for its long-standing dedication to the highest standards in surgical patient care.
  • View the full release here: https://www.businesswire.com/news/home/20231121829446/en/
    Children’s Hospital Los Angeles leadership and team members gather in front of the newly installed American College of Surgeons Surgical Quality Partner plaque.
  • The SQP designation lets patients know that Children’s Hospital Los Angeles is dedicated to relentless self-improvement and has been verified through a detailed and rigorous review from ACS.
  • “We are immensely proud to be named an ACS Surgical Quality Partner,” said James Stein, MD, MSc, FACS, FAAP, Senior Vice President and Chief Medical Officer at Children’s Hospital Los Angeles.

Kidneylink Announces Program Growth in Value-Based Kidney Care

Retrieved on: 
星期三, 十二月 13, 2023
NPS, Chronic kidney disease, Kidney disease, Associate, ESKD, Pharmacist, Risk, RNS, Patient, Nephrology, USRC, Dialysis, CKD, Kidney transplantation, MD, Partnership, Social, Growth, Physician, FASN, Quality of life, Hospital, HIV disease progression rates, Pharmaceutical industry, Nursing

PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care, is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD). Since its inception in 2021, Kidneylink has improved clinical outcomes for patients resulting in double-digit percentage reductions in hospitalizations and medical costs.

Key Points: 
  • PLANO, Texas, Dec. 13, 2023 /PRNewswire/ -- Kidneylink – a national, value-based kidney care company founded by U.S. Renal Care , is pleased to announce significant growth and success on behalf of its patients and providers – expanding its network to more than 600 nephrologists across 20 U.S. based markets and caring for more than 16,000 people living with kidney disease, both Chronic Kidney Disease (CKD) and End Stage Kidney Disease (ESKD).
  • Kidneylink is also not limited to U.S. Renal Care dialysis centers—more than 50% of Kidneylink ESKD patients are treated outside of USRC's facilities.
  • Many value-based kidney organizations rely on virtual care management teams that work around the nephrologist.
  • The future of kidney care is value-based care.

Boston Medical Center to Offer First FDA-Approved Gene Therapy Treatment Program for Sickle Cell Disease

Retrieved on: 
星期五, 十二月 8, 2023
BMC, Safety, Chronic pain, Life, Pulmonology, CRISPR Therapeutics, Therapy, Sickle cell disease, Disease, Risk, Vertex Pharmaceuticals, Clinical trial, Vertex, Patient, Nephrology, End organ damage, FDA, Conditional sentence, DSM-IV codes, CRISPR, Pain, Doctor of Philosophy, Volatile organic compound, SCD, Stroke, Blood, Boston Medical Center, Center of excellence, Pharmaceutical industry, Nursing, MD

BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology. The new therapy leverages the latest advances in medical science to alleviate the severe painful vaso-occlusive crises (VOCs) associated with sickle cell disease, in a long-awaited step toward equity for a disproportionally impacted Black patient population.

Key Points: 
  • BOSTON, Dec. 8, 2023 /PRNewswire/ -- Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.
  • The announcement comes as the FDA today granted approval of this new therapy, jointly developed by Boston-based Vertex Pharmaceuticals and CRISPR Therapeutics of Switzerland, along with approval of another cell-based gene therapy for sickle cell disease.
  • BMC is the only hospital in New England to offer the Vertex Pharmaceuticals and CRISPR Therapeutics therapy to eligible adults with sickle cell disease.
  • "Boston Medical Center has a longstanding commitment to providing advanced clinical care to those with sickle cell disease," said Dr. Jean-Antoine Ribeil, MD, PhD, Clinical Director of the Center of Excellence in Sickle Cell Disease at Boston Medical Center and an internationally renowned hematologist who has dedicated his career to the development of gene therapies for patients with sickle cell disease and beta thalassemia.